What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to inform investors that Boston Scientific has received key merger control clearances from regulatory bodies, specifically the U.S. Federal Trade Commission (FTC), for its proposed acquisition of BTG plc. It also confirms clearances from Spain and Austria.

Does this mean the acquisition of BTG plc is now complete?

No, receiving merger control clearance is a significant milestone, but it does not mean the acquisition is complete. It indicates that a major regulatory hurdle has been cleared. There may be other conditions precedent outlined in the original acquisition agreement that still need to be met before the transaction can be finalized.

What are the implications of the U.S. FTC clearance?

The U.S. FTC clearance under the HSR Act signifies that U.S. antitrust regulators have reviewed the acquisition and found no significant competition concerns that would prevent it from proceeding. This is a crucial step for any large acquisition involving U.S. entities or operations.

Are there any other regulatory approvals needed for the BTG acquisition?

The filing mentions clearances from Spain and Austria in addition to the U.S. The RNS announcement, incorporated by reference, would provide the most comprehensive details on all regulatory approvals obtained to date. However, it is common for such transactions to require approvals from multiple jurisdictions depending on the companies' global operations.

BSX 8-K SEC Disclosure

Summary

Boston Scientific Corporation (BSX) has filed an 8-K report on August 7, 2019, to announce a significant development regarding its previously announced acquisition of BTG plc. The company confirmed that the acquisition has received merger control clearance from the U.S. Federal Trade Commission (FTC) under the Hart-Scott-Rodino (HSR) Act. This clearance is a critical step towards completing the transaction, indicating that regulatory hurdles in the United States have been overcome. In addition to the U.S. clearance, the filing also notes that merger control approvals have been secured from other key jurisdictions, including the CNMC in Spain (July 25, 2019) and the Federal Competition Authority in Austria (August 2, 2019). These approvals collectively signal substantial progress in fulfilling the conditions precedent for the acquisition, bringing Boston Scientific closer to integrating BTG's operations and expanding its product portfolio. Investors should view this as a positive development, reducing uncertainty around the deal's completion.

Key Highlights

1Boston Scientific has received merger control clearance from the U.S. Federal Trade Commission (FTC) for its proposed acquisition of BTG plc.
2The clearance was granted under the Hart-Scott-Rodino (HSR) Act, a key regulatory requirement for large mergers and acquisitions in the U.S.
3The company also disclosed that merger control clearance has been obtained from Spain's CNMC and Austria's Federal Competition Authority.
4These regulatory approvals are critical steps towards the successful completion of the BTG acquisition.
5The filing includes an attached RNS announcement detailing these regulatory clearances.
6The company emphasizes that this 8-K is not an offer to sell or solicitations for votes/approvals related to the transaction.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Aug 7, 2019)

Summary

Key Highlights

Frequently Asked Questions